Cetuximab (Targeted Therapy)
Treatment for Lip And Oral Cavity Cancer
Typical Dosage: Loading dose 400 mg/m2, then 250 mg/m2 weekly
Effectiveness
65%
Safety Score
55%
Clinical Trials
2
Participants
50K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
55
DangerousModerateSafe
Treatment Details
Dosage Range
Loading dose 400 mg/m2, then 250 mg/m2 weekly
Time to Effect
Weeks
Treatment Duration
Weekly for 7-8 weeks with RT, or until progression for metastatic
Evidence Quality
HIGHNumber Needed to Treat (NNT)
10(Treat 10 patients to see 1 additional successful outcome)
Confidence Score
80%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$50,000
Monitoring:$8,000
Side Effect Mgmt:$3,000
Total Annual:$61,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$220,000/QALY
QALYs Gained
0.3
Outcome-Based Costs
Cost per Responder
$305,000
Cost per Remission
$1,220,000
Cetuximab (Targeted Therapy) Outcomes
for Lip And Oral Cavity Cancer
Efficacy Outcomes
Overall Effectiveness
+65%
Response Rate
+20%
Remission Rate
+5%
Common Side Effects
Acneiform rash
+75%
Hypomagnesemia
+40%
Fatigue
+40%
Infusion reactions
+15%
Paronychia
+15%
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
1 completed trial for Cetuximab (Targeted Therapy) in Lip And Oral Cavity Cancer
Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
NCT03082534COMPLETEDPHASE2
78 participants
INTERVENTIONAL
La Jolla, United States +3 more
Started: Mar 28, 2017